Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Tredje AP fonden

Tredje AP fonden cut its position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 50.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,080 shares of the medical research company's stock after selling 14,080 shares during the period. Tredje AP fonden's holdings in Exact Sciences were worth $791,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Exact Sciences by 63.6% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 549,262 shares of the medical research company's stock worth $30,863,000 after acquiring an additional 213,557 shares in the last quarter. AGF Management Ltd. purchased a new stake in shares of Exact Sciences during the 4th quarter worth approximately $2,667,000. Daiwa Securities Group Inc. boosted its holdings in shares of Exact Sciences by 2.1% in the 4th quarter. Daiwa Securities Group Inc. now owns 14,447 shares of the medical research company's stock valued at $812,000 after buying an additional 300 shares in the last quarter. Isthmus Partners LLC grew its position in shares of Exact Sciences by 8.9% in the 4th quarter. Isthmus Partners LLC now owns 12,227 shares of the medical research company's stock valued at $687,000 after buying an additional 1,000 shares during the last quarter. Finally, AlphaQuest LLC raised its stake in Exact Sciences by 22,825.0% during the 4th quarter. AlphaQuest LLC now owns 917 shares of the medical research company's stock worth $52,000 after acquiring an additional 913 shares in the last quarter. 88.82% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Exact Sciences Price Performance

Shares of Exact Sciences stock traded up $0.78 on Wednesday, hitting $45.70. The company's stock had a trading volume of 1,531,769 shares, compared to its average volume of 2,620,571. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. The firm has a fifty day moving average price of $51.24 and a 200-day moving average price of $58.58. Exact Sciences Co. has a 52-week low of $40.62 and a 52-week high of $79.62. The company has a market capitalization of $8.49 billion, a P/E ratio of -8.20 and a beta of 1.25.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The business had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. On average, equities research analysts expect that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on EXAS shares. Bank of America dropped their price target on Exact Sciences from $72.00 to $65.00 and set a "buy" rating on the stock in a research report on Thursday, February 20th. Scotiabank upped their price target on Exact Sciences from $70.00 to $73.00 and gave the stock a "sector outperform" rating in a research note on Monday, February 24th. Royal Bank of Canada began coverage on shares of Exact Sciences in a research note on Thursday, March 13th. They issued a "sector perform" rating and a $52.00 price objective on the stock. BTIG Research upped their price objective on shares of Exact Sciences from $65.00 to $75.00 and gave the stock a "buy" rating in a research report on Tuesday, November 26th. Finally, Barclays lowered their target price on shares of Exact Sciences from $70.00 to $65.00 and set an "overweight" rating on the stock in a report on Thursday, February 20th. Two analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $70.83.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.